DBV Technologies 배당금 및 환매

배당금 기준 확인 0/6

DBV Technologies 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

0.5%

환매 수익률

총 주주 수익률	0.5%
미래 배당 수익률	0%
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

DBV Technologies S.A.'s (EPA:DBV) 41% Share Price Surge Not Quite Adding Up

Oct 24

Analysts Just Made A Major Revision To Their DBV Technologies S.A. (EPA:DBV) Revenue Forecasts

Aug 04

Risks To Shareholder Returns Are Elevated At These Prices For DBV Technologies S.A. (EPA:DBV)

Jun 14

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For DBV Technologies S.A.'s (EPA:DBV) CEO For Now

May 10

DBV Technologies S.A. (EPA:DBV) Released Earnings Last Week And Analysts Lifted Their Price Target To €6.50

May 09

Some DBV Technologies S.A. (EPA:DBV) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 14

DBV Technologies S.A. (EPA:DBV) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 10

Here's Why We're Not Too Worried About DBV Technologies' (EPA:DBV) Cash Burn Situation

Oct 04

DBV Technologies S.A. (EPA:DBV) Shares Could Be 45% Below Their Intrinsic Value Estimate

Aug 06

Here's Why DBV Technologies (EPA:DBV) Must Use Its Cash Wisely

Mar 14

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 DBV 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: DBV 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

DBV Technologies 시장 대비 배당 수익률

DBV 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (DBV)	n/a
시장 하위 25% (FR)	2.1%
시장 상위 25% (FR)	5.5%
업계 평균 (Biotechs)	1.6%
애널리스트 예측 (DBV) (최대 3년)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 DBV 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 DBV 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 DBV 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: DBV 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

DBV Technologies 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

DBV Technologies Announces Plan to Implement ADS Ratio Change to Regain Compliance

Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.17 loss in 3Q 2023)

DBV Technologies S.A.'s (EPA:DBV) 41% Share Price Surge Not Quite Adding Up

New major risk - Revenue and earnings growth

Dbv Technologies Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and Europe

Price target decreased by 48% to €2.45

Consensus revenue estimates decrease by 18%

Analysts Just Made A Major Revision To Their DBV Technologies S.A. (EPA:DBV) Revenue Forecasts

Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.26 loss in 2Q 2023)

DBV Technologies S.A. to Report Q2, 2024 Results on Jul 30, 2024

New minor risk - Share price stability

DBV Technologies Provides Non-Compliance Update Related to Nasdaq Listing Rule 5550(a)(2) & 5810(c)(3)(A)

Risks To Shareholder Returns Are Elevated At These Prices For DBV Technologies S.A. (EPA:DBV)

Consensus EPS estimates upgraded to US$0.74 loss, revenue downgraded

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For DBV Technologies S.A.'s (EPA:DBV) CEO For Now

DBV Technologies S.A. (EPA:DBV) Released Earnings Last Week And Analysts Lifted Their Price Target To €6.50

Price target increased by 36% to €6.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Insufficient new directors

DBV Technologies S.A., Annual General Meeting, May 16, 2024

New minor risk - Profitability

No longer forecast to breakeven

Some DBV Technologies S.A. (EPA:DBV) Analysts Just Made A Major Cut To Next Year's Estimates

DBV Technologies S.A. (EPA:DBV) Just Reported Earnings, And Analysts Cut Their Target Price

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 17% to €4.43

New major risk - Financial position

DBV Technologies S.A. to Report Fiscal Year 2023 Results on Mar 07, 2024

Forecast to breakeven in 2026

DBV Technologies Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?

DBV Technologies S.A. to Present New Data at ACAAI 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 29%

DBV Technologies S.A. to Report Q3, 2023 Results on Oct 31, 2023

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Announces Executive Changes

Dbv Technologies S.A. Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies

Second quarter 2023 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2022)

DBV Technologies S.A. to Report First Half, 2023 Results on Jul 31, 2023

New minor risk - Shareholder dilution

Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 18%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates decrease by 26%

We're Hopeful That DBV Technologies (EPA:DBV) Will Use Its Cash Wisely

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to €5.64

Forecast to breakeven in 2025

DBV Technologies Announces FDA Lifts Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

Price target decreased to €5.16

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

DBV Technologies S.A. Announces Executive Changes

Here's Why We're Not Too Worried About DBV Technologies' (EPA:DBV) Cash Burn Situation

Consensus forecasts updated

DBV Technologies S.A. Receives Feedback from the U.S. Food and Drug Administration in the Form of a Partial Clinical Hold on Its VITESSE Phase 3 Clinical Study

DBV Technologies S.A. Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

Consensus EPS estimates fall by 11%

Consensus revenue estimates increase by 53%

DBV Technologies S.A. (EPA:DBV) Shares Could Be 45% Below Their Intrinsic Value Estimate

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

DBV Technologies S.A. announced that it has received €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, Fairmount Funds Management LLC

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies Announces Positive Topline Results from Phase 3 Epitope Trial of Viaskin Peanut in Peanut-Allergic Toddlers

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Here's Why DBV Technologies (EPA:DBV) Must Use Its Cash Wisely

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

DBV Technologies S.A. to Report Q1, 2022 Results on May 02, 2022

Consensus forecasts updated